New data show excellent quality-of-life outcomes and effective tumor control for both intensity-modulated radiation therapy ...

Astellas Pharma is slowing things down in the inaugural consumer-facing marketing blast for eye disease drug Izervay. | ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Astellas is rolling out its first DTC campaign to raise awareness about an injection that treats geographic atrophy.

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Singlera Genomics and Astellas Pharma presented results during the JSOT 2024 Annual Meeting demonstrating that drug-induced ...

The Federal Circuit has vacated a District of Delaware ruling in a patent case which found that patent claims asserted by ...

Zydus Lifesciences has received a significant approval from the US FDA for Enzalutamide capsules, which are used in treatment ...

ASP-2138 is a bispecific antibody targeting CD3 and claudin 18.2 (CLDN18.2). It is administered through intravenous drip ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Uneasiness among Japanese residents in China may accelerate a shift away from the country following a series of incidents ...

Patient-reported quality of life (QoL) was similar between proton beam therapy (PBT) and intensity-modulated radiation ...